Royalty Pharma vs Revolution Medicines
Royalty Pharma (RPRX), health care, and Revolution Medicines (RVMD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Royalty Pharma is worth $39.5B on the stock market and Revolution Medicines $35.2B: Royalty Pharma is valued at 12% more. Over the past year Royalty Pharma's share price has moved +73.7% and Revolution Medicines's +136%.
Key facts
- Royalty Pharma market value
- $39.5B
- Revolution Medicines market value
- $35.2B
- Royalty Pharma P/E
- 44.9
- Royalty Pharma revenue
- $2.4BFY to 2025-12-31
- Revolution Medicines revenue
- $0FY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Royalty Pharma | Revolution Medicines |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $39.5Bhigher | $35.2Blower |
| Revenue | $2.4Bhigher | $0lower |
| Earnings | $770.9Mhigher | -$1.1Blower |
| Employees | 100lower | 883higher |
| Total assets | $19.6Bhigher | $2.4Blower |
| Valuation | ||
| P/E | 44.9 | — |
| P/S | 16.6 | — |
| P/B | 4.5lower | 14.7higher |
| Dividend yield | 1.35%higher | 0.00%lower |
| Profitability | ||
| Operating margin | 65.6% | — |
| Balance sheet | ||
| Net assets | $9.7Bhigher | $1.6Blower |
| Total liabilities | $9.9Bhigher | $723.2Mlower |
| Total debt | $9B | — |
| Cash on hand | $618.7Mhigher | $383.7Mlower |
| Price change | ||
| Today | +0.23%higher | -2.50%lower |
| 1 year | +73.7%lower | +136%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Royalty Pharma only (5)
- Pat Dorsey8.2%
- Samantha McLemore6.7%
- Baillie Gifford team0.5%
- Murray Stahl0.3%
- Paul Tudor Jones0.1%
Revolution Medicines only (5)
- Andrew Spokes14.4%
- Julian and Felix Baker10.7%
- Stanley Druckenmiller1.7%
- Brandon Haley0.6%
- Louis Bacon0.5%
Percentages are each holding's share of that investor's reported portfolio. Who owns RPRX · Who owns RVMD
More on Royalty Pharma
Further comparisons
Royalty Pharma against its closest peers
Revolution Medicines against its closest peers
Learn
Questions and answers
Which is bigger, Royalty Pharma or Revolution Medicines?
By market value, Royalty Pharma is the larger: $39.5B against $35.2B for Revolution Medicines. By revenue in its latest fiscal year, Royalty Pharma is the larger: $2.4B against $0 for Revolution Medicines.
Which has the higher dividend yield?
Royalty Pharma: 1.35%, against 0.00% for Revolution Medicines. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Royalty Pharma and Revolution Medicines?
None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Royalty Pharma and 5 hold Revolution Medicines.
Cite this page
Funkfolio, “Royalty Pharma vs Revolution Medicines”, data as of 18 November 2026. https://funkfolio.com/compare/rprx-vs-rvmd
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.